Analysis Tools|
Allele Symbol Allele Name Allele ID |
Ncr1+ wild type MGI:2435768 |
||||||||||||||||||||||||
| Summary |
5 genotypes
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
| N |
• mice show no significant variation in numbers fo lymphoid and myeloid subsets compared with wild-type; NK cell counts and in vitro effector function are normal
|
|
• mice are born at normal Mendelian frequencies, are viable and fertile
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• mice show subtle changes in the expression of NK cell surface receptors and a defect in NK cell maturation with a 5-fold reduction of CD27+CD11b+ NK cells in spleen and a 2.7-fold loss of CD27+CD11b+ NK cells in the bone marrow
|
|
• mice show a 1.3-fold increase in the number of immature CD27+CD11b- NK cells in bone marrow but no significant change in spleen
|
|
• number of NK cells (Lin-CD122+DX5+) is decreased 4-fold in spleen and 1.5-fold in the bone marrow
|
|
• mice show a 9-fold reduction of mature CD27-CD11b+ NK cells in spleen, and 4-fold loss of CD27-CD11b+ NK cells in the bone marrow
|
|
• mice show a 2-fold reduction in the % of proliferating Ki67+CD11b- NK cells in the bone marrow, with no change in the % of Ki67+CD11b+ cells
• splenic CD11b- NK cells show no change in Ki67 staining, and even a small increase in the CD11b+ fraction relative to controls (10.8% vs 6.8%)
• annexin V staining showed a modest reduction of cell death CD11b- NK cells in the bone marrow relative to controls (10% vs 14%) but no significant change in splenic CD11b- NK cells
• CD11b+ NK cells show a 2-fold increase in annexin V staining in the bone marrow and a 3-fold increase in spleen
• however, activation of mTOR in response to IL-15 stimulation is normal in immature NK cells
|
|
• mice exhibit reduced clearance of MHC class I-deficient tumors in vivo; 48 h after i.p. injection, recovery of RMA/s tumor cells is 6.5% versus 1.8% in control mice
• in an in vitro YAC-1 target lysis assay, splenic NK cells (DX5+) show 53% of the cytotoxic activity seen in control mice at a 2:1 E:T ratio
|
|
• mice show subtle changes in the expression of NK cell surface receptors and a defect in NK cell maturation with a 5-fold reduction of CD27+CD11b+ NK cells in spleen and a 2.7-fold loss of CD27+CD11b+ NK cells in the bone marrow
|
|
• mice show a 1.3-fold increase in the number of immature CD27+CD11b- NK cells in bone marrow but no significant change in spleen
|
|
• number of NK cells (Lin-CD122+DX5+) is decreased 4-fold in spleen and 1.5-fold in the bone marrow
|
|
• mice show a 9-fold reduction of mature CD27-CD11b+ NK cells in spleen, and 4-fold loss of CD27-CD11b+ NK cells in the bone marrow
|
|
• mice show a 2-fold reduction in the % of proliferating Ki67+CD11b- NK cells in the bone marrow, with no change in the % of Ki67+CD11b+ cells
• splenic CD11b- NK cells show no change in Ki67 staining, and even a small increase in the CD11b+ fraction relative to controls (10.8% vs 6.8%)
• annexin V staining showed a modest reduction of cell death CD11b- NK cells in the bone marrow relative to controls (10% vs 14%) but no significant change in splenic CD11b- NK cells
• CD11b+ NK cells show a 2-fold increase in annexin V staining in the bone marrow and a 3-fold increase in spleen
• however, activation of mTOR in response to IL-15 stimulation is normal in immature NK cells
|
|
• mice exhibit reduced clearance of MHC class I-deficient tumors in vivo; 48 h after i.p. injection, recovery of RMA/s tumor cells is 6.5% versus 1.8% in control mice
• in an in vitro YAC-1 target lysis assay, splenic NK cells (DX5+) show 53% of the cytotoxic activity seen in control mice at a 2:1 E:T ratio
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
| N |
• mice are born in Mendelian ratios and survive without any overt phenotype
|
|
• mice show a defect in NK cell maturation with a 1.8-fold reduction of CD27+CD11b+ NK cells in the bone marrow and a 3-fold loss of CD27+CD11b+ NK cells in spleen
|
|
• mice show a 1.4-fold increase in the number of immature CD27+CD11b- NK cells in bone marrow but no significant change in spleen
|
|
• mice exhibit reduced numbers of peripheral NK cells with a 2.9-fold reduction of NK cell number in spleen
• however, NK cell number is normal in the bone marrow
|
|
• mice show a 6-fold reduction of mature CD27-CD11b+ NK cells in spleen, and 3-fold loss of CD27-CD11b+ NK cells in the bone marrow
|
|
• mice show a defect in NK cell maturation with a 1.8-fold reduction of CD27+CD11b+ NK cells in the bone marrow and a 3-fold loss of CD27+CD11b+ NK cells in spleen
|
|
• mice show a 1.4-fold increase in the number of immature CD27+CD11b- NK cells in bone marrow but no significant change in spleen
|
|
• mice exhibit reduced numbers of peripheral NK cells with a 2.9-fold reduction of NK cell number in spleen
• however, NK cell number is normal in the bone marrow
|
|
• mice show a 6-fold reduction of mature CD27-CD11b+ NK cells in spleen, and 3-fold loss of CD27-CD11b+ NK cells in the bone marrow
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• in the spleen, blood, and liver
• mice infected with murine cytomegalovirus exhibit reduced total and Ly49H+ after 1.5 days infection and milder after 3.5 days compared with control mice
|
|
• decreased survival in vivo and in culture
• treatment with IL2-anti-IL2 complexes partially rescues the ability to reject B2m-deficient splenocytes
• slightly less granzyme A production in uninfected mice
• however, cells exhibit normal cell-mediated immunity when cultured with RMA-S and RMA-H60 target cells
• however, increased IL2 or IL15 amounts restores NK cell survival in culture
|
|
• mice infected with murine cytomegalovirus exhibit reduced total and Ly49H+ after 1.5 days infection and milder after 3.5 days with reduced granzyme B production and higher viral loads early after infection in the spleen and lungs compared with control mice
• however, IFNG production from NK cells of cytomegalovirus virus-infected mice
|
|
• in the spleen, blood, and liver
• mice infected with murine cytomegalovirus exhibit reduced total and Ly49H+ after 1.5 days infection and milder after 3.5 days compared with control mice
|
|
• decreased survival in vivo and in culture
• treatment with IL2-anti-IL2 complexes partially rescues the ability to reject B2m-deficient splenocytes
• slightly less granzyme A production in uninfected mice
• however, cells exhibit normal cell-mediated immunity when cultured with RMA-S and RMA-H60 target cells
• however, increased IL2 or IL15 amounts restores NK cell survival in culture
|
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO) |
||
|
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support. |
last database update 03/18/2025 MGI 6.24 |
|
|
|
||
